Genprex CROIC

Mitä Genprex tekee? Genprex, Inc. generates revenue through the development and potential commercialization of its gene therapy products, including Oncoprex, an immunogene therapy for cancer treatment. Oncoprex utilizes a tumor suppressor gene licensed from The University of Texas MD Anderson Cancer Center, designed to modulate the immune system and target cancer cells. The company also develops a pre-clinical gene therapy for diabetes, licensed from the University of Pittsburgh, which aims to treat both type 1 and type 2 diabetes. These therapies are intended to be used alongside targeted therapies and immunotherapies for non-small cell lung cancer (NSCLC). The primary buyers of Genprex's products are expected to be healthcare providers and pharmaceutical companies seeking innovative treatments for cancer and diabetes. The company's focus on clinical-stage development means it currently does not have commercial products but aims to advance its therapies through clinical trials to secure partnerships or direct sales. The target segments include patients with non-small cell lung cancer and those with type 1 or type 2 diabetes who require new therapeutic options. Genprex's revenue model relies on licensing agreements with academic institutions like MD Anderson and the University of Pittsburgh for the use of their gene technologies. The company also seeks to form strategic partnerships with pharmaceutical firms to co-develop and commercialize its therapies. These partnerships are expected to provide funding for further development and eventual market entry. Genprex on yksi Eurpooliin suosituimmista yhtiöistä.